REFERENCES
- Hunter T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 1995; 80: 225–236, [PUBMED], [INFOTRIEVE]
- Alaimo P J, Shogren-Knaak M A, Shokat K M. Chemical genetic approaches for the elucidation of signaling pathways. Curr Opin Chem Biol 2001; 5: 360–367, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lawrence D S, Niu J. Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol Ther 1998; 77: 81–114, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Parang K, Till J H, Ablooglu A J, Kohanski R A, Hubbard S R, Cole P A. Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol 2001; 8: 37–41, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Minor L K. Assays to measure the activation of membrane tyrosine kinase receptors: Focus on cellular methods. Curr Opin Drug Discov Devel 2003; 6(5)760–765, [PUBMED], [INFOTRIEVE], [CSA]
- Braun S, Raymond W E, Racker E. Synthetic tyrosine polymers as substrates and inhibitors of tyrosine-specific protein kinases. J Biol Chem 1984; 259: 2051–2054, [PUBMED], [INFOTRIEVE]
- Zeller M, Essmann F, Janicke R U, Schulze-Osthoff K, Konig S. A rapid nonradioactive peptide phosphorylation assay. J Exp Ther Oncol 2003; 3: 59–61, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Farley K, Mett H, Mc Glynn E, Murray B, Lyndon N B. Development of solid-phase enzyme-linked immunosorbent assay for the determination of epidermal growth factor receptor and pp60c-src tyrosine kinase protein kinase activity. Anal Biochem 1992; 203: 151–157, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Erös D, Kövesdi I, Örfi L, Takács-Novák K, Acsády G, Kéri G. Reliability of logP predictions based on calculated molecular descriptors: A critical review. Curr Med Chem 2002; 9: 1819–1829
- Jorissen R N, Walker F, Pouliot N, Garrett T P, Ward C W, Burgess A W. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31–53, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Varkondi E, Schafer E, Bökönyi G, Gyökeres T, Hamvas J, Kéri G, Schwab R, Pap A. Comparison of ELISA-based tyrosine kinase assays for screening EGFR inhibitors (35th European Pancreatic Club (EPC) Meeting, Liverpool, UK, June 18–22, 2003). Pancreatology 2003; 3: 209–269, [CROSSREF]
- Fry D W, Kraker A J, Mc Michael A, Ambroso L A, Nelson J M, Leopold W R, Connors R W, Bridges A J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994; 265: 1093–1095, [PUBMED], [INFOTRIEVE]
- Gazit A, Chen J, App H, Mc Mahon G, Hirth P, Chen I, Levitzki A. Tyrphostins IV - Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorg Med Chem 1996; 4: 1203–1207, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bridges A J. Chemical inhibitors of protein kinases. Chem Rev 2001; 101: 2541–2572, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bridges A J. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999; 6: 825–843, [PUBMED], [INFOTRIEVE]
- Lynch T J, Bell D W, Sordella R, Gurubhagavatula S, Okimoto R A, Brannigan B W, Harris P L, Haserlat S M, Supko J G, Haluska F G, Louis D N, Christiani D C, Settleman J, Haber D A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. 2004; 350: 2129–2139
- Normanno N, Di Maio M, Perrone F. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?. Journal of Clinical Oncology 2004; 22: 2035–2037, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Osborne R. Mutation, rash clues may sharpen focus for EGFR cancer therapies. Bioworld Today 2004; 15: 1–7, [CSA]